JFL Life Sciences Limited
NNSE:JFLLIFE10.30
INR
-0.50
(-4.63%)
ISIN
INE0LA901015
Return %
Stock
S&P 500
1Y
-16.26
14.20
3Y
-36.22
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Semi-annual Revenue
INR
•
in mil. unless spec.Semi-annual Earnings Per Share
INR
•
in mil. unless spec.Semi-annual Dividends Per Share
INR
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Ahmedabad India
- IPO Date
- Sep 8, 2022
- Website
- jfllifesciences.com
- Similar Companies
- Business
- JFL Life Sciences Limited is an India-based pharmaceutical company engaged in the manufacturing, marketing, and contract development of a broad spectrum of pharmaceutical formulations for domestic and international healthcare markets. Founded in 2010 and headquartered in Ahmedabad, Gujarat, India, the company operates two World Health Organization Good Manufacturing Practices (WHO-GMP) certified production units located in Bavla, Ahmedabad, dedicated to sterile dry powder injectables and solid oral dosage forms. The company's core product portfolio encompasses multiple therapeutic categories and dosage forms, comprising dry powder injectables, including Beta-Lactam antibiotic formulations such as ampicillin, amoxicillin, cefazolin sodium, ceftriaxone sodium, cefuroxime sodium, and cefotaxime sodium; Beta-Lactam solid oral formulations, including generic and branded tablets and capsules such as amoxicillin and amoxicillin-clavulanate combinations; general solid oral formulations, including non-Beta-Lactam tablets and capsules spanning anti-infectives, analgesics, antipyretics, gastrointestinal therapies, anti-inflammatory agents, and anti-malarials such as azithromycin, ciprofloxacin, ofloxacin, metronidazole, and co-trimoxazole; liquid oral preparations, including therapeutic syrups and pediatric suspensions; and oral rehydration salts (ORS) electrolyte powders. Beyond proprietary commercial marketing, the company provides end-to-end contract manufacturing, third-party loan-license formulation services, and private-label production for domestic pharmaceutical companies and institutional buyers. Geographically, JFL Life Sciences supplies healthcare distributors across India and exports formulations to international markets across Africa, the Middle East, Southeast Asia, and the Commonwealth of Independent States (CIS) region, supported by product registrations and merchant export networks across countries including Kenya, Nigeria, Yemen, Cambodia, Myanmar, Ukraine, Uzbekistan, and Kazakhstan. In recent corporate developments, the company executed a 1:1 rights issue in March 2026 to augment its equity base, support working capital requirements, and finance operational scaling across its manufacturing infrastructure. JFL Life Sciences has also expanded its dossier filings and international regulatory approvals across targeted export destinations, while solidifying governance and strategic direction through the re-appointment of its executive leadership team, including the Managing Director and Executive Director, to steer ongoing production capacity enhancements and global distribution partnerships.